The short answer
Biased agonism means a ligand preferentially activates some downstream pathways over others at the same receptor. At the GLP-1 receptor, favouring cAMP signalling while limiting β-arrestin recruitment reduces receptor internalisation, prolonging signalling. Tirzepatide shows this bias; native GLP-1 does not.
Key facts
- Definition
- Ligand-specific preference among downstream pathways
- Pathway favoured
- cAMP / G protein
- Pathway limited
- β-arrestin recruitment
- Consequence
- Reduced receptor internalisation
- Result
- Prolonged signalling from the cell surface
- Example
- Tirzepatide at GLP-1R
- Key reference
- PMID 33268378
What a receptor does after it is activated
Activation is not the end of the story. A G-protein-coupled receptor engages G proteins, generating second messengers such as cAMP, and separately recruits β-arrestin. β-arrestin does two things: it uncouples the receptor from G protein signalling, and it drives internalisation, pulling the receptor off the cell surface. That is the normal mechanism by which a signal is switched off.
Where bias comes in
Different ligands binding the same receptor can favour these arms to different degrees. A ligand producing strong cAMP signalling with weak β-arrestin recruitment activates the receptor without efficiently triggering its own shutdown. The receptor stays at the plasma membrane and keeps signalling. This ligand-specific preference is what biased agonism means, and it is a property of the ligand, not of the receptor.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why this matters for incretin drugs
Reported work shows that biased signalling toward cAMP with limited β-arrestin recruitment prevents internalisation at both GLP-1R and GIPR, and that GLP-1 analogues with selectively reduced β-arrestin-2 recruitment produce less endocytosis and more sustained insulin secretion. At GLP-1R, tirzepatide favours cAMP accumulation over β-arrestin recruitment and is less effective at inducing internalisation than the native ligand, retaining receptor at the surface and generating greater efficacy.
A better explanation than 'it adds GIP'
Tirzepatide's advantage over semaglutide is usually attributed entirely to GIP receptor agonism. Biased signalling at the GLP-1 receptor is a second, independent contribution, and it may account for part of the gap. This matters because it makes the GIP paradox less puzzling: if some of tirzepatide's edge comes from how it signals rather than from which receptors it hits, then a GIPR antagonist producing comparable results is less contradictory than it first appears.
The design implication
If bias is a tunable property, it becomes a design target alongside receptor selectivity and half-life. Work has reported GLP-1 analogues optimised specifically for cAMP-biased signalling, and dual GLP-1R/GIPR biased agonism has been reported to yield greater efficacy than bias at either receptor alone. This is a different axis of optimisation from adding receptors, and the two can be pursued together.
What remains uncertain
Much of this work is preclinical or in cell systems, and the relationship between measured bias in an assay and clinical outcome in a person is not simple. Bias is also assay-dependent. The same ligand can appear differently biased depending on what is measured and in which cell type. Treat it as an active and promising area rather than a settled explanation.
Frequently asked questions
What is β-arrestin?
A protein recruited to activated GPCRs that uncouples them from G protein signalling and drives their internalisation. It is the normal off-switch.
Does biased agonism explain tirzepatide's advantage?
Partly, perhaps. It is a second contribution alongside GIP receptor agonism, and it is not yet established how much of the clinical difference it accounts for.
Is more bias always better?
Not established. Bias is assay-dependent and the link between measured bias and clinical outcome is not straightforward.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBiased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signalling (PMID 33268378)pubmed.ncbi.nlm.nih.gov
- PubMedRodriguez R et al., Biased agonism of GLP-1R and GIPR. Cell Rep Med 2025 (PMID 40460831)pubmed.ncbi.nlm.nih.gov
- PubMedTran HD et al., Modelling G protein-biased agonism at GLP-1R. Mol Metab 2026 (PMID 41570980)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Albumin Binding and Half-Life ExtensionA fatty acid chain that binds albumin turns a peptide cleared in minutes into one dosed weekly. How chain length tunes it from liraglutide to retatrutide.
- What Is Pramlintide? The First Clinical Amylin AnaloguePramlintide solved amylin's aggregation problem with three prolines borrowed from rat amylin. Why it needed meal-time dosing and cagrilintide does not.
- What Is Oxyntomodulin? Nature's Dual AgonistOxyntomodulin is a gut peptide that activates both GLP-1 and glucagon receptors. It is the biological precedent every GLP-1/glucagon dual agonist is built on.
- GLP-1 Agonists and Alcohol Use: The Trial EvidenceThree randomised trials have tested semaglutide in alcohol use disorder, reporting reduced craving and heavy drinking days. All were small and short.
- SURMOUNT-OSA: Tirzepatide in Obstructive Sleep ApnoeaTirzepatide reduced apnoea-hypopnoea index by 27.4 events per hour at 52 weeks against 4.8 on placebo. The first incretin approved for a non-metabolic use.